Search results
Added:
1 year ago
Dr Bernardo Cortese (La Fondazione Ricerca e Innovazione Cardiovascolare, IT) discusses the findings from the EASTBOURNE Registry, a study that investigated the sirolimus-coated balloon in an all-comer population.
Findings are positive in regard to the device's safety and efficacy profile, with no safety signals for bleeding and the primary endpoint of target lesion revascularization (TLR), was…
View more
Coronary Arteries and Sirolimus-eluting Stents - Applications, Benefits and Future Potential
Added:
3 years ago
Article
Added:
3 years ago
“I do not know what I may appear to the world, but to myself I seem to have been only like a boy playing on the sea-shore, diverting myself in now and then finding a smoother pebble or a prettier shell than ordinary, whilst the great ocean of truth lay all undiscovered before me.” Sir Isaac Newton
Advances in Percutaneous Coronary Intervention – An Overview
Over the last 10 years, the…
View more
Added:
1 year ago
CRT 23 - In this short interview, we are joined by Dr Bernardo Cortese (Fondazione Ricerca e InnovazioneCardiovascolare, IT, DCB Academy, IT,Cardio Parc, FR) to outline the findings from a prespecified sub-analysis of the EASTBOURNE study. In this trial, investigators aimed to evaluate the performance of a sirolimus-coated balloon to treat coronary lesions. This sub-analysis collected and…
View more
Added:
2 years ago
In this video, Professor Bruno Scheller (Saarland University, Saarbrücken, DE) sits down to discuss the one-year angiographic outcomes of two parallel randomized trials investigating the effectiveness off sirolimus-coated and paclitaxel-coated DCB's in the treatment of coronary in-stent restenosis. Findings suggest comparable outcomes in both devices.
Discussion points:
1. Importance of this…
View more
Added:
3 years ago
An unintended consequence of the market success of drug-eluting stents has been a growing concern about their safety and safety-related costs. These devices have been so quickly and widely adopted that their market penetration already equals that of some of the most popular pharmaceutical drugs. Consequently, the absolute significance of even a low incidence of side effects becomes magnified by…
View more
Added:
3 years ago
Drug-eluting stents (DES) are the standard percutaneous treatment strategy in patients with coronary artery disease (CAD). Their use has further reduced the incidence of restenosis and repeat revascularisation in single vessel de novo disease. These stents have bioactive coatings that, through a complex mechanism, allow the release of various anti-inflammatory and anti-proliferative drugs at high…
View more
Added:
3 years ago
Drug-eluting stents (DES) have been recognised as a ‘breakthrough technology’ since 2003 due to their unique capacity to reduce clinical restenosis. The difference in restenosis rates, as assessed by angiography, was so large between DES and bare-metal stents (BMS) in the first trials – 0% versus 26% after six months in the first published trial (RAVEL) with the sirolimus-eluting stent (SES),1…
View more
Added:
3 years ago
An unintended consequence of the market success of drug-eluting stents has been a growing concern about their safety and safety-related costs. These devices have been so quickly and widely adopted that their market penetration already equals that of some of the most popular pharmaceutical drugs. Consequently, the absolute significance of even a low incidence of side effects becomes magnified by…
View more
Added:
3 years ago
More than 170 million people suffer from diabetes mellitus worldwide and their number is growing continuously. About 65% of diabetics die of cardiovascular disease and diabetes accounts for over a quarter of percutaneous coronary interventions (PCIs).
Diabetes mellitus has been consistently shown to be an important predictor of poor outcomes after PCI. Diabetic patients have an increased risk…
View more
